MDG_LOGO_2016_GRAY_RGB.jpg
Medigene to Present at ESMO Congress 2024
23 juil. 2024 05h15 HE | Medigene AG
Planegg/Martinsried, July 23, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
cmi_logo.png
[Latest] Global Epigenetics Diagnostic Market Size/Share Worth USD 41.6 Billion by 2033 at a 14.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
23 juil. 2024 03h30 HE | Custom Market Insights
Austin, TX, USA, July 23, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Epigenetics Diagnostic Market Size, Trends and Insights By Product Type...
OBT-RGB_1417_544 (2).jpg
Oxford BioTherapeutics Named Best Tech SME of the Year at Thames Valley Tech & Innovation Awards 2024
22 juil. 2024 08h00 HE | Oxford BioTherapeutics
Oxford, UK and San Jose, California, 22 July 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based...
shph logo wire.jpg
Shuttle Pharma’s Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE
19 juil. 2024 09h00 HE | Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., July 19, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
nouscom logo.png
Nouscom Appoints Tiffany Muller as Chief Financial Officer and Loredana Siani as Senior Vice President, Technical and CMC Development
17 juil. 2024 03h00 HE | Nouscom Srl
BASEL, Switzerland – 17th July 2024 - Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, today...
Flag_logo.jpg
FLAG Therapeutics Announces Encouraging Preclinical Data from Studies of FLAG-003 for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)
16 juil. 2024 09h00 HE | Flag Therapeutics, Inc.
FLAG Therapeutics Announces Encouraging Preclinical Data from Studies of FLAG-003 for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)
Tevogen Logo Notified.png
Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback
11 juil. 2024 12h21 HE | Tevogen Bio Inc
WARREN, N.J., July 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holding Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing...
RM Primary Logo - Humble.png
Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer
11 juil. 2024 12h00 HE | Revolution Medicines, Inc.
Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in...
American Hospital Dubai
ICPO Foundation kooperiert mit dem American Hospital Dubai, um ein ICPO Collaborating Center im Nahen Osten zu etablieren.
11 juil. 2024 00h00 HE | ICPO Foundation
Diese Kooperation stärkt die globalen Bildungsstandards für Radiotheranostics und wird den Patientenzugang zu einer neuen Generation effektiver Krebstherapien in den Vereinigten Arabischen Emiraten...
American Hospital Dubai
ICPO Foundation partners with the American Hospital Dubai to establish an ICPO Collaborating Center in the Middle East.
11 juil. 2024 00h00 HE | ICPO Foundation
This cooperation strengthens global educational standards for radiotheranostics and will scale patient access to a new generation of effective cancer therapeutics in United Arabic Emirates. July 11,...